Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPAGTC · Entity 121949 | Chief Scientific Officer | August 15, 2020 | August 18, 2020 |
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, CHIEF SCIENTIFIC OFFICER | February 13, 2023 | February 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
APPLIED GENETIC TECHNOLOGIES CORP
Report date August 15, 2020 · Filed August 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,277 |
Reported balance
After 2020-08-15 transaction · row 1
1 source rowRow 1 · 2020-08-15 · Tax withholding · Disposed 5,723 · Balance 33,277 |
Editas Medicine, Inc.
Report date February 13, 2023 · Filed February 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,559 |
Reported balance
After 2023-02-13 transaction · row 1
1 source rowRow 1 · 2023-02-13 · Sale · Disposed 2,790 · Balance 65,559 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 15, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,790 | $9.67 | $26,966.19 |
DisclosureSEC source: 0001415889-23-002604 · form4-02152023_040213.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,559 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 16:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,145 | $10.06 | $51,744.81 |
DisclosureSEC source: 0001415889-22-006631 · form4-06162022_040601.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,349 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units and in performance stock units on June 14, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 16:21 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 93,398 | $0.00 Strike: $17.29 | $0.00 |
DisclosureSEC source: 0001415889-22-001224 · form4-02112022_010249.xml · derivative · entry 2 Shearman Mark S · CIK 0001643799 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,398 Underlying: Common Stock · 93,398 shares Expires 2032-02-09 F2 · derivative.exercise_date: This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 16:21 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 31,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001224 · form4-02112022_010249.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,494 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 16:10 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 9,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011225 · edgar.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,785 F1 · kind: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 14, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 14, 2022, subject to continued service. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 16:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 52,718 | $0.00 Strike: $38.53 | $0.00 |
DisclosureSEC source: 0001179110-21-006778 · edgar.xml · derivative · entry 2 Shearman Mark S · CIK 0001643799 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,718 Underlying: Common Stock · 52,718 shares Expires 2031-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2021 and is scheduled to vest over four years, with 25% of the shares to vest on June 14, 2022 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 14, 2025. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 16:19 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 32,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006778 · edgar.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,701 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 14, 2022 continuing through June 14, 2025. Read SEC document |
| August 15, 2020 Filed Aug 18, 2020 18:15 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | Tax withholdingCommon Stock | 5,723 | $5.77 | $33,021.71 |
DisclosureSEC source: 0001273636-20-000004 · edgar.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,277 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 20:07 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-20-021803 · doc4.xml · derivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-08-05 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 19:57 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000035 · edgar.xml · derivative · entry 2 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2029-08-15 F2 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 19:57 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001273636-19-000035 · edgar.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Applied Genetic Technologies Corporation ("AGTC") 2013 Equity and Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of AGTC common stock. The RSUs vest annually over two years beginning on the date of grant, with all such vesting contingent on the achievement of the average of the closing price per share of AGTC common stock, as quoted on the Nasdaq Global Market, over a consecutive, 30 trading day period reaching or exceeding $3.75 per share. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:58 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | SaleCommon Stock | 3,000 | $3.35 | $10,052.70 |
DisclosureSEC source: 0001273636-18-000081 · edgar.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36, inclusive. The reporting person undertakes to provide to Applied Genetic Technologies Corporation ("AGTC"), any security holder of AGTC, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 17:05 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001273636-18-000022 · edgar.xml · derivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 20:40 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0000899243-17-018472 · doc4.xml · derivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-07-17 F1 · derivative.exercise_date: The option becomes exercisable in equal monthly installments over four years from the date of grant. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 17:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | PurchaseCommon Stock | 1,300 | $8.87 | $11,531.00 |
DisclosureSEC source: 0000899243-16-030015 · doc4.xml · nonDerivative · entry 2 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 17:20 UTC | APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949 | PurchaseCommon Stock | 1,700 | $8.87 | $15,070.50 |
DisclosureSEC source: 0000899243-16-030015 · doc4.xml · nonDerivative · entry 1 Shearman Mark S · CIK 0001643799 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.